BNTX:NASDAQ
BioNTech SE - ADR
$96.40
arrow_downward
-1.76%(-1.73) 1D
$97.14
arrow_upward
+0.77% (+0.74)todayPre-market
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$97.50
High
$97.50
Low
$95.85
Mkt. cap
24.22B
Avg. vol.
1.54M
Volume
1.04K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.80
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$97.50
High
$97.50
Low
$95.85
Mkt. cap
24.22B
Avg. vol.
1.54M
Volume
1.04K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.80
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
ad-hoc-news.de
·
17 hours ago
BioNTech's Handover Year: Insider Selling, a Halved Revenue Base, and a Pipeline Under the Microscop
Simply Wall Street
·
1 day ago
BioNTech (BNTX) Ends Colorectal Trial As Fair Value Narrative Faces A Fresh Test
ad-hoc-news.de
·
1 day ago
BioNTech's Insider Trades and Pipeline Bet: Two Signals, One Stock
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR